Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1873 Meta-Analysis of Liver Resection versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases

Introduction: Available data comparing the efficacy of different treatment regiments are rarely found. No meta-analyses have compared live resection with other nonsurgical treatments in resectable liver metastases from pNETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Yuan C,

Keywords: meta-analysis, pancreatic neuroendocrine tumors (p-NETs) , liver metastasis, liver resection,

#1742 Nucleolin (NCL) Regulates Aerobic Glycolysis in Pancreatic Neuroendocrine Tumor (p-NET) BON-1 Cells

Introduction: NCL, a nucleolus localized protein and ribosomal RNA (rRNA) expression regulator, has been reported to function as an oncogene in several tumors. However, the expression and role of NCL in p-NET remains unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jin K, Yu X,

Keywords: pancreatic neuroendocrine tumors (p-NETs), Nucleolin (NCL), ribosomal RNA, ATP, aerobic glycolysis,

#1690 18F-FDG-PET to Discriminate Biologically Malignant Pancreatic Neuroendocrine Tumors

Introduction: 18F-FDG-PET is widely used to detect malignant tumors. However, the efficacy for pancreatic neuroendocrine tumors (PNETs) is reported to be limited in the clinical practice.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Sato A, Toshihiko M, Kenzo N, Yuichiro U, Yuji N,

Keywords: 18F-FDG-PET, pancreatic neuroendocrine tumors (p-nets), metastasis,

#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sansovini M

Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,

Keywords: PRRT, FDG-PET, P-NET,